Discontinuation of FX-322 (drug for sensorineural hearing loss) development
A specific drug development project involving FX-322, licensed from Frequency Therapeutics, for which Phase 2 development in sensorineural hearing loss was discontinued and an impairment loss was recognized on the in-licensed intangible asset.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.